Effect of Proton Pump Inhibitors on Endothelial Function
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
In this randomized controlled crossover study, the investigators propose to test the
hypothesis that proton pump inhibitors (PPIs) increase plasma levels of asymmetric
dimethylarginine (ADMA), which is a marker of endothelial dysfunction. The authors propose to
evaluate ADMA concentrations and vascular function analysis in healthy volunteers and adults
with a history of cardiovascular disease given PPI vs placebo for four weeks each.